Steadybase.

Parabilis Medicines, Inc.

Website Investor relations LinkedIn
  • PBLS ยท Nasdaq
  • Pharmaceutical Preparations
  • Cambridge, MA
  • CIK 0001657677

Updated from SEC filings through

Top things to know

Executives

Parabilis Medicines, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Cambridge, MA. It trades as PBLS on Nasdaq.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Mathai Mammen President & CEO Form 3, June 9, 2026
Thomas Rodolpho Kotarakos Chief Financial Officer Form 3, June 9, 2026
Mohammed Fawzi Benzaghou Chief Medical Officer Form 3, June 9, 2026
Teresa Jurgensen General Counsel Form 3, June 9, 2026

What Parabilis Medicines, Inc. does

- Innovation - R&D Focus - About Helicons - Platform - Programs - Publications - Patients - Expanded Access Statement - Company - Leadership - How We Got Here - Culture - Investors - Overview - News & Events - News Releases - Events - Presentations - Stock - Stock Quote & Chart - Corporate Governance - Documents & Charters - Leadership - Committee Composition - Financial Information - SEC Filings - Shareholder Services - Investor FAQs - Email Alerts - Contact Us

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Reportable segments 1 (period ending September 30, 2026) 10-Q, November 12, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
July 22, 2026 Capital Management L.P. Ra
Director
Buy 244,593 $6.9M Form 4, July 22, 2026
July 22, 2026 Peter Kolchinsky
Director
Buy 244,593 $6.9M Form 4, July 22, 2026
July 22, 2026 Rajeev M. Shah
Director
Buy 244,593 $6.9M Form 4, July 22, 2026
July 22, 2026 Capital Nexus Fund L.P. RA III
Director
Buy 244,593 $6.9M Form 4, July 22, 2026
July 22, 2026 Capital Healthcare Fund LP RA
Director
Buy 244,593 $6.9M Form 4, July 22, 2026
June 15, 2026 Alan Sebulsky
Director
Buy 17,500 $474K Form 4, June 16, 2026
June 11, 2026 Capital Nexus Fund L.P. RA III
Director
Buy 21,188,750 $424M Form 4, June 15, 2026
June 11, 2026 Capital Healthcare Fund LP RA
Director
Buy 21,188,750 $424M Form 4, June 15, 2026

Recent 8-K events

  • 8-K filed 2026-11-12
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-11-05
    • Item 1.01 Entry into a material definitive agreement
  • 8-K filed 2026-09-15
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-09-02
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-08-25
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-08-13
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-06-11
    • Item 1.01 Entry into a material definitive agreement
    • Item 3.02 Unregistered sales of equity securities
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year

Frequently asked questions about Parabilis Medicines, Inc.

What does Parabilis Medicines, Inc. do?
In its own words, from Item 1 of its 10-K: "- Innovation - R&D Focus - About Helicons - Platform - Programs - Publications - Patients - Expanded Access Statement - Company - Leadership - How We Got Here - Culture - Investors - Overview - News & Events - News Releases - Events - Presentations - Stock - Stock Quote & Chart - Corporate Governance - Documents & Charters - Leadership - Committee Composition - Financial Information - SEC Filings - Shareholder Services - Investor FAQs - Email Alerts - Contact Us"
Who is the CFO of Parabilis Medicines, Inc.?
Thomas Rodolpho Kotarakos, Chief Financial Officer, as named in a 3 filed June 9, 2026.
Where is Parabilis Medicines, Inc. headquartered?
Cambridge, MA.
What is Parabilis Medicines, Inc.'s stock ticker?
PBLS on Nasdaq.
What industry is Parabilis Medicines, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Parabilis Medicines, Inc.'s website?
parabilismed.com. Investor relations: https://investors.parabilismed.com/.
When does Parabilis Medicines, Inc. report earnings next?
November 30, 2026. Source: sec_8k.
Is Parabilis Medicines, Inc. a public company?
Yes. Parabilis Medicines, Inc. files with the SEC under CIK 0001657677 and trades as PBLS.
How many business segments does Parabilis Medicines, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
Have Parabilis Medicines, Inc. insiders traded stock recently?
Since June 11, 2026, officers and directors reported 0 open-market sales and 12 purchases worth about $2.2B on Forms 4 and 5. The most recent: Capital Management L.P. Ra (Director) bought 244,593 shares on July 22, 2026.